Annual Report FY26 with variation of preferential issue and related party investment

Related Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.1%Reaction day

₹29.10

prior close

₹29.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+4.6% vs market

Non Banking Financial Company (NBFC) peers, median of 225sector+0.1%+4.0% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.0 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+1.6

15m

+1.6

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.1-0.4+4.6+0.1+4.0

Next day

-2.9+0.2-3.1+0.6-3.5

+2.9-0.1+3.0+0.7+2.2

+2.2+0.2+2.0+0.0+2.2

+1.9+0.5+1.4+0.6+1.4

-0.3-0.4+0.2-0.2-0.1

+2.1-0.4+2.5-0.8+2.8

15d

+1.2-2.5+3.7-1.4+2.6

-0.3+0.3-0.6-1.5+1.1

+20.3-9.4+29.7-6.4+26.7

—————

UpDownMarket · Nifty Microcap 250Sector · Non Banking Financial Company (NBFC) peers, median of 225Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Prism Medico submitted its Annual Report for FY 2025-26 and called the 24th AGM for Sept 19, 2026. Key proposal: vary the Rs. 25 crore preferential issue to discontinue plant and civil works allocation of Rs. 23 crore and instead invest in Infuze Well Private Limited, a related party, making it a 71.32 percent subsidiary. Also seeks approval for related party transactions up to Rs. 70 crore, re-appoints statutory auditors, and appoints secretarial auditors for 5 years.

Likely market impact

Major capital reallocation from manufacturing capex to acquiring a related party as subsidiary, plus omnibus approval for related party deals up to Rs. 70 crore.